# Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

> **NCT02712983** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 107 (actual)

## Conditions studied

- Non-cystic Fibrosis Bronchiectasis

## Interventions

- **DRUG:** TIP
- **DRUG:** TIP and placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02712983
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-08
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2020-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02712983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02712983, "Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02712983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*